Condition
Sensory System Agents
Total Trials
5
Recruiting
2
Active
2
Completed
1
Success Rate
50.0%-36% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 3 (1)
P 4 (1)
Trial Status
Recruiting2
Completed1
Terminated1
Unknown1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06462196Recruiting
Natural History of Depression, Bipolar Disorder and Suicide Risk
NCT06752759Phase 3Recruiting
Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting
NCT05615948Phase 4Completed
Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
NCT04309084Phase 1Unknown
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
NCT04489420Phase 1Terminated
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
Showing all 5 trials